person · Reporting owner

MCKEON BRIAN P

Disclosed activity across 4 companies

Tapewire entity: 38418
SEC CIK: 0001219445

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Alkermes plc.ALKS · Entity 2392	Director	May 20, 2026	May 23, 2026
DENTSPLY SIRONA Inc.XRAY · Entity 4448	Director	June 12, 2026	June 15, 2026
IDEXX LABORATORIES INC /DEIDXX · Entity 3057	EVP, CFO and Treasurer	February 14, 2025	February 19, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Alkermes plc.

Report date May 20, 2026 · Filed May 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	38,536	Ending reported balance After 2026-05-21 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-05-21 · Exercise / conversion · Acquired 6,142 · Balance 40,011 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. Row 2 · 2026-05-21 · Tax withholding · Disposed 1,475 · Balance 38,536
Non Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.98 · Expires 2036-05-20	Direct	11,538	Reported balance After 2026-05-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-20 · Grant · Acquired 11,538 · Balance 11,538 F3: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.
Restricted Stock Unit AwardSEC Table II · derivative / convertible security	Direct	5,409	Reported balance After 2026-05-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-05-20 · Grant · Acquired 5,409 · Balance 5,409 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F3: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.
Restricted Stock Unit AwardSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-05-21 · Exercise / conversion · Disposed 6,142 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F4: This award is fully vested in accordance with its terms.
Ordinary SharesSEC Table I · non-derivative	IndirectBy the Brian P. McKeon Trust	10,000	Reported balance Holding disclosure · report date 2026-05-20 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 10,000 F2: Shares are held by The Brian P. McKeon Revocable Trust, dated April 12, 2007 and amended and restated on February 8, 2019 (the "Brian P. McKeon Trust"), of which the reporting person and his wife are the trustees and members of the reporting person's immediate family are the beneficiaries.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2: Shares are held by The Brian P. McKeon Revocable Trust, dated April 12, 2007 and amended and restated on February 8, 2019 (the "Brian P. McKeon Trust"), of which the reporting person and his wife are the trustees and members of the reporting person's immediate family are the beneficiaries.

F3: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.

F4: This award is fully vested in accordance with its terms.

DENTSPLY SIRONA Inc.

Report date June 12, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy a Trust	10,000	Reported balance After 2026-06-12 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-06-12 · Purchase · Acquired 10,000 · Balance 10,000
Common StockSEC Table I · non-derivative	Direct	28,887	Reported balance Holding disclosure · report date 2026-06-12 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 28,887

IDEXX LABORATORIES INC /DE

Report date February 14, 2025 · Filed February 19, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	31,208.5926	Reported balance After 2025-02-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2025-02-14 · Exercise / conversion · Acquired 252 · Balance 31,208.5926 F1: Includes a total of 25 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2024 and December 31, 2024.
Common StockSEC Table I · non-derivative	Direct	31,511.5926	Reported balance After 2025-02-14 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2025-02-14 · Exercise / conversion · Acquired 303 · Balance 31,511.5926
Common StockSEC Table I · non-derivative	Direct	31,819.5926	Reported balance After 2025-02-14 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2025-02-14 · Exercise / conversion · Acquired 308 · Balance 31,819.5926
Common StockSEC Table I · non-derivative	Direct	32,118.5926	Reported balance After 2025-02-14 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2025-02-14 · Exercise / conversion · Acquired 299 · Balance 32,118.5926
Common StockSEC Table I · non-derivative	Direct	31,549.5926	Reported balance After 2025-02-14 transaction · row 5 Account or security details depend on footnotes; rows are not merged. 1 source row Row 5 · 2025-02-14 · Tax withholding · Disposed 569 · Balance 31,549.5926
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-02-14 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-02-14 · Exercise / conversion · Disposed 252 · Balance 0 F2: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	303	Reported balance After 2025-02-14 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-02-14 · Exercise / conversion · Disposed 303 · Balance 303 F3: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2023.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	615	Reported balance After 2025-02-14 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-02-14 · Exercise / conversion · Disposed 308 · Balance 615 F4: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2024.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	894	Reported balance After 2025-02-14 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-02-14 · Exercise / conversion · Disposed 299 · Balance 894 F5: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning on February 14, 2025.
Common StockSEC Table I · non-derivative	Indirectby Estony McKeon Family, LLC	18,050	Reported balance Holding disclosure · report date 2025-02-14 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 18,050

Filing footnotes · ownership attribution and instrument terms

F1: Includes a total of 25 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2024 and December 31, 2024.

F2: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022.

F3: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2023.

F4: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2024.

F5: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning on February 14, 2025.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ATHENAHEALTH INC

Report date February 11, 2019 · Filed February 13, 2019

Section 16 reporting ended · disclosed 2019-02-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-02-11 transaction · row 1 1 source row Row 1 · 2019-02-11 · Disposition to issuer · Disposed 2,721 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of November 11, 2018, among athenahealth, Inc. (the "Company"), May Holding Corp., and May Merger Sub Inc. (the "Merger Agreement"), on February 11, 2019, each share of athenahealth common stock, par value $0.01 ("Common Stock") issued and outstanding immediately prior to the Effective Time (as defined in the Merger Agreement) and not otherwise excluded pursuant to the terms of the Merger Agreement, was converted into the right to receive $135.00 per share in cash (the "Merger Consideration"), subject to any required withholding taxes. F2: 1,931 of these securities represent shares of Common Stock underlying athenahealth restricted stock unit ("RSU") awards subject to time-based vesting. Pursuant to the Merger Agreement, on February 11, 2019, unvested RSUs outstanding immediately prior to the Effective Time were canceled and converted into the right to receive the Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of November 11, 2018, among athenahealth, Inc. (the "Company"), May Holding Corp., and May Merger Sub Inc. (the "Merger Agreement"), on February 11, 2019, each share of athenahealth common stock, par value $0.01 ("Common Stock") issued and outstanding immediately prior to the Effective Time (as defined in the Merger Agreement) and not otherwise excluded pursuant to the terms of the Merger Agreement, was converted into the right to receive $135.00 per share in cash (the "Merger Consideration"), subject to any required withholding taxes.

F2: 1,931 of these securities represent shares of Common Stock underlying athenahealth restricted stock unit ("RSU") awards subject to time-based vesting. Pursuant to the Merger Agreement, on February 11, 2019, unvested RSUs outstanding immediately prior to the Effective Time were canceled and converted into the right to receive the Merger Consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 08, 2021 Filed Nov 10, 2021 22:31 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	10,000	$67.85	$678,500.00	Disclosure SEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,316.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 9 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2021. Read SEC document
August 05, 2021 Filed Aug 9, 2021 21:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	192	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-014771 · doc1.xml · derivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,658 Underlying: Common Stock · 192 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. F3 · price: Not applicable. F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. F2 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. Read SEC document
August 05, 2021 Filed Aug 9, 2021 21:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Tax withholdingCommon Stock	96	$705.76	$67,752.96	Disclosure SEC source: 0001567619-21-014771 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,307.6426 Read SEC document
August 05, 2021 Filed Aug 9, 2021 21:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	192	$0.00	$0.00	Disclosure SEC source: 0001567619-21-014771 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,403.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 23.6426 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2021 and June 30, 2021. Read SEC document
August 02, 2021 Filed Aug 4, 2021 20:46 UTC	Alkermes plc. ALKS · Entity 2392	PurchaseOrdinary Shares	10,000	$26.43	$264,269.00	Disclosure SEC source: 0001127602-21-023084 · form4.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Brian P. McKeon Trust Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.41 to $26.44. Full information regarding the number of shares purchased at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. F2 · ownership.nature: The reporting person and his wife are trustees of The Brian P. McKeon Revocable Trust, dated April 12, 2007 and amended and restated on February 8, 2019 (the "Brian P. McKeon Trust"), and members of the reporting person's immediate family are beneficiaries of the trust. Read SEC document
June 14, 2021 Filed Jun 16, 2021 20:27 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	7,585	$0.00	$0.00	Disclosure SEC source: 0001127602-21-020045 · form4.xml · derivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,585 Underlying: Ordinary Shares · 7,585 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/14/2022. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/14/2022. Read SEC document
June 14, 2021 Filed Jun 16, 2021 20:27 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	15,677	$0.00 Strike: $24.72	$0.00	Disclosure SEC source: 0001127602-21-020045 · form4.xml · derivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,677 Underlying: Ordinary Shares · 15,677 shares Expires 2031-06-14 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/14/2022. Read SEC document
February 18, 2021 Filed Feb 19, 2021 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative	1,474	Not disclosed Strike: $67.85	Not disclosed	Disclosure SEC source: 0001567619-21-004515 · doc1.xml · derivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,474 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy 4,395 shares of IDEXX Laboratories, Inc. common stock that became exercisable in one installment on February 14, 2021. Read SEC document
February 18, 2021 Filed Feb 19, 2021 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	1,474	$67.85	$100,010.90	Disclosure SEC source: 0001567619-21-004515 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 16, 2021 Filed Feb 18, 2021 00:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	1,307	$539.58	$705,231.06	Disclosure SEC source: 0001567619-21-004326 · doc1.xml · nonDerivative · entry 7 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,714 Read SEC document
February 14, 2021 Filed Feb 18, 2021 00:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	433	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-004326 · doc1.xml · derivative · entry 16 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,850 Underlying: Common Stock · 433 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F11 · price: Not applicable. F10 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F10 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. Read SEC document
February 14, 2021 Filed Feb 18, 2021 00:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	435	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-004326 · doc1.xml · derivative · entry 15 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,283 Underlying: Common Stock · 435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F11 · price: Not applicable. F9 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F9 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document
February 14, 2021 Filed Feb 18, 2021 00:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	505	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-004326 · doc1.xml · derivative · entry 14 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,718 Underlying: Common Stock · 505 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F11 · price: Not applicable. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. Read SEC document
February 14, 2021 Filed Feb 18, 2021 00:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	459	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-004326 · doc1.xml · derivative · entry 13 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,223 Underlying: Common Stock · 459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F11 · price: Not applicable. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. Read SEC document
February 14, 2021 Filed Feb 18, 2021 00:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	810	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-004326 · doc1.xml · derivative · entry 12 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,682 Underlying: Common Stock · 810 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2017. F11 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2017. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2017. Read SEC document
February 14, 2021 Filed Feb 18, 2021 00:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantRestricted Stock Unit · Derivative	1,011	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-004326 · doc1.xml · derivative · entry 11 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,492 Underlying: Common Stock · 1,011 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F11 · price: Not applicable. F5 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F5 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. Read SEC document
February 14, 2021 Filed Feb 18, 2021 00:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantIncentive Stock Option (right-to-buy) · Derivative	183	Not disclosed Strike: $544.08	Not disclosed	Disclosure SEC source: 0001567619-21-004326 · doc1.xml · derivative · entry 10 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183 Underlying: Common Stock · 183 shares Expires 2021-02-13 F2 · derivative.exercise_price: Closing price of Issuer common stock on the NASDAQ Global Select Market on February 12, 2021. F11 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on the fourth anniversary of the date of grant. Read SEC document
February 14, 2021 Filed Feb 18, 2021 00:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantNon-Qualified Stock Option (right-to-buy) · Derivative	9,538	Not disclosed Strike: $544.08	Not disclosed	Disclosure SEC source: 0001567619-21-004326 · doc1.xml · derivative · entry 9 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,538 Underlying: Common Stock · 9,538 shares Expires 2031-02-13 F2 · derivative.exercise_price: Closing price of Issuer common stock on the NASDAQ Global Select Market on February 12, 2021. F11 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2022. Read SEC document
February 14, 2021 Filed Feb 18, 2021 00:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Tax withholdingCommon Stock	1,335	$544.08	$726,346.80	Disclosure SEC source: 0001567619-21-004326 · doc1.xml · nonDerivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,021 Read SEC document
February 14, 2021 Filed Feb 18, 2021 00:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	433	$0.00	$0.00	Disclosure SEC source: 0001567619-21-004326 · doc1.xml · nonDerivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2021 Filed Feb 18, 2021 00:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	435	$0.00	$0.00	Disclosure SEC source: 0001567619-21-004326 · doc1.xml · nonDerivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2021 Filed Feb 18, 2021 00:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	505	$0.00	$0.00	Disclosure SEC source: 0001567619-21-004326 · doc1.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2021 Filed Feb 18, 2021 00:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	459	$0.00	$0.00	Disclosure SEC source: 0001567619-21-004326 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2021 Filed Feb 18, 2021 00:33 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	810	$0.00	$0.00	Disclosure SEC source: 0001567619-21-004326 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 14 shares purchased under the Issuer's Employee Stock Purchase Plan on December 31, 2020. Read SEC document
February 10, 2021 Filed Feb 11, 2021 22:28 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	2,223	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-21-005257 · form4.xml · derivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,223 Underlying: Ordinary Shares · 2,223 shares Expires not disclosed F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 2/10/2022. F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 2/10/2022. Read SEC document
February 10, 2021 Filed Feb 11, 2021 22:28 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	4,549	$0.00 Strike: $22.93	$0.00	Disclosure SEC source: 0001127602-21-005257 · form4.xml · derivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,549 Underlying: Ordinary Shares · 4,549 shares Expires 2031-02-10 F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 2/10/2022. Read SEC document
February 10, 2021 Filed Feb 11, 2021 22:28 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	13,336	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-21-005257 · form4.xml · derivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,336 Underlying: Ordinary Shares · 13,336 shares Expires not disclosed F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 2/10/2022. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 2/10/2022. Read SEC document
February 10, 2021 Filed Feb 11, 2021 22:28 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	26,169	$0.00 Strike: $22.93	$0.00	Disclosure SEC source: 0001127602-21-005257 · form4.xml · derivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,169 Underlying: Ordinary Shares · 26,169 shares Expires 2031-02-10 F1 · derivative.exercise_date: Shares subject to the stock option award vest in three annual installments commencing on 2/10/2022. Read SEC document
November 06, 2020 Filed Nov 11, 2020 00:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	3,000	$478.13	$1,434,380.40	Disclosure SEC source: 0001567619-20-019112 · doc1.xml · nonDerivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Indirect · by Estony McKeon Family, LLC Disclosed balance after: 18,050 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $477.86 to a high of $478.26 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
November 06, 2020 Filed Nov 11, 2020 00:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	2,100	$476.89	$1,001,465.85	Disclosure SEC source: 0001567619-20-019112 · doc1.xml · nonDerivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Indirect · by Estony McKeon Family, LLC Disclosed balance after: 21,050 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $476.51 to a high of $477.61 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
November 06, 2020 Filed Nov 11, 2020 00:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	300	$475.50	$142,650.00	Disclosure SEC source: 0001567619-20-019112 · doc1.xml · nonDerivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Indirect · by Estony McKeon Family, LLC Disclosed balance after: 23,150 Read SEC document
November 06, 2020 Filed Nov 11, 2020 00:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	3,338	$475.02	$1,585,625.11	Disclosure SEC source: 0001567619-20-019112 · doc1.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Indirect · by Estony McKeon Family, LLC Disclosed balance after: 23,450 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $474.38 to a high of $475.32 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
November 06, 2020 Filed Nov 11, 2020 00:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	1,241	$474.14	$588,403.77	Disclosure SEC source: 0001567619-20-019112 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Indirect · by Estony McKeon Family, LLC Disclosed balance after: 26,788 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $473.42 to a high of $474.32 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
November 06, 2020 Filed Nov 11, 2020 00:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	21	$472.88	$9,930.53	Disclosure SEC source: 0001567619-20-019112 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Indirect · by Estony McKeon Family, LLC Disclosed balance after: 28,029 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $472.36 to a high of $473.36 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
November 04, 2020 Filed Nov 6, 2020 22:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative	36,216	Not disclosed Strike: $79.54	Not disclosed	Disclosure SEC source: 0001567619-20-018871 · doc1.xml · derivative · entry 17 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,216 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F16 · price: Not applicable. F15 · derivative.exercise_date: Grant of option to buy 18,108 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document
November 04, 2020 Filed Nov 6, 2020 22:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	200	$481.26	$96,252.00	Disclosure SEC source: 0001567619-20-018871 · doc1.xml · nonDerivative · entry 15 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,700 Read SEC document
November 04, 2020 Filed Nov 6, 2020 22:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	566	$480.31	$271,853.65	Disclosure SEC source: 0001567619-20-018871 · doc1.xml · nonDerivative · entry 14 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,900 F14 · price: Represents the weighted average price of the shares sold ranging from a low of $480.17 to a high of $480.53 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
November 04, 2020 Filed Nov 6, 2020 22:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	1,534	$479.69	$735,851.36	Disclosure SEC source: 0001567619-20-018871 · doc1.xml · nonDerivative · entry 13 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,466 F13 · price: Represents the weighted average price of the shares sold ranging from a low of $479.14 to a high of $480.135 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
November 04, 2020 Filed Nov 6, 2020 22:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	390	$477.02	$186,036.44	Disclosure SEC source: 0001567619-20-018871 · doc1.xml · nonDerivative · entry 12 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 F12 · price: Represents the weighted average price of the shares sold ranging from a low of $476.785 to a high of $477.25 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
November 04, 2020 Filed Nov 6, 2020 22:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	3,596	$476.01	$1,711,739.87	Disclosure SEC source: 0001567619-20-018871 · doc1.xml · nonDerivative · entry 11 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,390 F11 · price: Represents the weighted average price of the shares sold ranging from a low of $475.70 to a high of $476.51 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
November 04, 2020 Filed Nov 6, 2020 22:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	3,474	$475.20	$1,650,846.19	Disclosure SEC source: 0001567619-20-018871 · doc1.xml · nonDerivative · entry 10 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,986 F10 · price: Represents the weighted average price of the shares sold ranging from a low of $474.63 to a high of $475.63 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
November 04, 2020 Filed Nov 6, 2020 22:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	244	$473.97	$115,648.17	Disclosure SEC source: 0001567619-20-018871 · doc1.xml · nonDerivative · entry 9 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,460 F9 · price: Represents the weighted average price of the shares sold ranging from a low of $473.5275 to a high of $474.46 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
November 04, 2020 Filed Nov 6, 2020 22:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	2,407	$473.04	$1,138,601.74	Disclosure SEC source: 0001567619-20-018871 · doc1.xml · nonDerivative · entry 8 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,704 F8 · price: Represents the weighted average price of the shares sold ranging from a low of $472.46 to a high of $473.46 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
November 04, 2020 Filed Nov 6, 2020 22:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	1,107	$472.20	$522,720.97	Disclosure SEC source: 0001567619-20-018871 · doc1.xml · nonDerivative · entry 7 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,111 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $471.44 to a high of $472.34 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
November 04, 2020 Filed Nov 6, 2020 22:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	2,493	$471.02	$1,174,258.84	Disclosure SEC source: 0001567619-20-018871 · doc1.xml · nonDerivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,218 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $470.43 to a high of $471.43 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
November 04, 2020 Filed Nov 6, 2020 22:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	2,850	$469.80	$1,338,920.88	Disclosure SEC source: 0001567619-20-018871 · doc1.xml · nonDerivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,711 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $469.40 to a high of $470.37 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
November 04, 2020 Filed Nov 6, 2020 22:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	9,617	$469.09	$4,511,280.84	Disclosure SEC source: 0001567619-20-018871 · doc1.xml · nonDerivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,561 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $468.39 to a high of $469.39 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
November 04, 2020 Filed Nov 6, 2020 22:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	6,338	$467.97	$2,965,969.78	Disclosure SEC source: 0001567619-20-018871 · doc1.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,178 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $467.38 to a high of $468.38 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
November 04, 2020 Filed Nov 6, 2020 22:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	1,400	$467.01	$653,819.88	Disclosure SEC source: 0001567619-20-018871 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,516 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $466.36 to a high of $467.31 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
November 04, 2020 Filed Nov 6, 2020 22:07 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	36,216	$79.54	$2,880,620.64	Disclosure SEC source: 0001567619-20-018871 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,916 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 18 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2020 and excludes 28,050 shares previously owned directly which were contributed to the Estony McKeon Family, LLC on August 21, 2020. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.